GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » Debt-to-Revenue

Ovoca Bio (DUB:OVXA) Debt-to-Revenue : N/A (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ovoca Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. Ovoca Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. Ovoca Bio's annualized Revenue for the quarter that ended in Jun. 2023 was €0.00 Mil.


Ovoca Bio Debt-to-Revenue Historical Data

The historical data trend for Ovoca Bio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Debt-to-Revenue Chart

Ovoca Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Ovoca Bio Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Ovoca Bio's Debt-to-Revenue

For the Biotechnology subindustry, Ovoca Bio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovoca Bio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's Debt-to-Revenue falls into.



Ovoca Bio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ovoca Bio's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Ovoca Bio's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Ovoca Bio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovoca Bio (DUB:OVXA) Business Description

Traded in Other Exchanges
Address
17 Pembroke Street Upper, Dublin, IRL, D02 AT22
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio (DUB:OVXA) Headlines

No Headlines